Temozolomide Plus Radiotherapy Improves Survival in Non-Co-Deleted Glioma
Combination treatment of temozolomide plus radiotherapy improves survival in non-co-deleted gliomas.
Participants receiving TTFields with temozolomide experienced significantly longer deterioration-free survival for global health vs those receiving temozolomide only.
The FDA has granted full approval of Avastin for the treatment of glioblastoma.
Treatment with lomustine plus bevacizumab does not show a survival advantage over treatment with lomustine alone in patients with glioblastoma.